SCHEMBL15910801

SCHEMBL15910801

CC(C)[C@@H](N)CNc1c(-c2nc3cc(N4CCOCC4)ccc3[nH]2)c(=O)[nH]c2cc(Cl)ccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 15/20 0.47
KDR P35968 13/20 0.47
PDGFRB P09619 11/20 0.47
FLT1 P17948 6/20 0.46
FLT3 P36888 2/20 0.40
CHEK1 O14757 3/20 0.40
EGFR P00533 2/20 0.40
INSR P06213 2/20 0.40
LCK P06239 2/20 0.40
IGF1R P08069 2/20 0.40
PTK2 Q05397 2/20 0.40
CYP3A4 P08684 2/20 0.40
ERBB2 P04626 1/20 0.40
CYP1A2 P05177 1/20 0.40
MET P08581 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAP2K1 Q02750 1/20 0.40
PLK4 O00444 1/20 0.40
AURKA O14965 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15910800 1.00 FGFR1 (0.47) FGFR1KDRPDGFRBFLT1FLT3
SCHEMBL3381313 0.95 FGFR1 (0.52) FGFR1KDRPDGFRBFLT1FLT3
SCHEMBL3381326 0.95 FGFR1 (0.52) FGFR1KDRPDGFRBFLT1FLT3
SCHEMBL3378274 0.91 FGFR1 (0.58) FGFR1KDRPDGFRBFLT1CHEK1
SCHEMBL3381041 0.91 FGFR1 (0.58) FGFR1KDRPDGFRBFLT1CHEK1
SCHEMBL14795509 0.87 FGFR1 (0.47) FGFR1KDRPDGFRBFLT1FLT3
SCHEMBL14795445 0.86 FGFR1 (0.61) FGFR1KDRPDGFRBFLT1CHEK1
SCHEMBL14795447 0.86 FGFR1 (0.61) FGFR1KDRPDGFRBFLT1CHEK1
SCHEMBL14796127 0.85 FGFR1 (0.46) FGFR1KDRPDGFRBFLT1FLT3
SCHEMBL14796018 0.85 FGFR1 (0.46) FGFR1KDRPDGFRBFLT1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2762475-A1 Pharmaceutically acceptable salts of quinolinone compounds and their medical use Novartis Vaccines and Diagnostics, Inc. (US) 2014-08-06 EP disclosed